Is KOD or RGNX more profitable?

Kodiak Sciences has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -273.23% -85.48% REGENXBIO -112.58% -220.07% -46.04%

Does the media favor KOD or RGNX?

In the previous week, Kodiak Sciences had 61 more articles in the media than REGENXBIO. MarketBeat recorded 64 mentions for Kodiak Sciences and 3 mentions for REGENXBIO. Kodiak Sciences' average media sentiment score of 0.61 beat REGENXBIO's score of 0.53 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 17 Very Positive mention(s) 7 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RGNX or VCEL?

Vericel has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.87 -$193.88M -$3.79 N/A Vericel $276.26M 7.31 $16.52M $0.47 83.91

Is RGNX or VCEL more profitable?

Vericel has a net margin of 7.91% compared to REGENXBIO's net margin of -112.58%. Vericel's return on equity of 6.91% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Vericel 7.91% 6.91% 5.02%

Does the media refer more to RGNX or VCEL?

In the previous week, REGENXBIO and REGENXBIO both had 3 articles in the media. Vericel's average media sentiment score of 0.78 beat REGENXBIO's score of 0.53 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, RGNX or MESO?

Mesoblast has lower revenue, but higher earnings than REGENXBIO. Mesoblast is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.87 -$193.88M -$3.79 N/A Mesoblast $120.25M 15.47 -$57.50M -$0.28 N/A

Is RGNX or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Mesoblast's return on equity of 0.00% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% Mesoblast N/A N/A N/A

Does the media favor RGNX or MESO?

In the previous week, Mesoblast had 4 more articles in the media than REGENXBIO. MarketBeat recorded 7 mentions for Mesoblast and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.53 beat Mesoblast's score of 0.45 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

REGENXBIO (RGNX) Competitors

$7.42 -0.11 (-1.46%)

Closing price 10/1/2026 04:00 PM Eastern

Extended Trading

$7.55 +0.13 (+1.75%)

As of 10/1/2026 07:30 PM Eastern

Compare

RGNX vs. KOD, VCEL, MESO, AGIO, and LKFT

Should you buy REGENXBIO stock or one of its competitors? REGENXBIO's main competitors and comparable companies include Kodiak Sciences (KOD), Vericel (VCEL), Mesoblast (MESO), Agios Pharmaceuticals (AGIO), and Lakefront Biotherapeutics American Depositary Shares (LKFT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does REGENXBIO compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and REGENXBIO (NASDAQ:RGNX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kodiak Sciences has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

REGENXBIO has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
REGENXBIO	$170.44M	2.87	-$193.88M	-$3.79	N/A

In the previous week, Kodiak Sciences had 61 more articles in the media than REGENXBIO. MarketBeat recorded 64 mentions for Kodiak Sciences and 3 mentions for REGENXBIO. Kodiak Sciences' average media sentiment score of 0.61 beat REGENXBIO's score of 0.53 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	17 Very Positive mention(s)	7 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
REGENXBIO	-112.58%	-220.07%	-46.04%

Kodiak Sciences presently has a consensus target price of $100.43, indicating a potential upside of 2.00%. REGENXBIO has a consensus target price of $23.27, indicating a potential upside of 213.65%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

REGENXBIO beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to Vericel?

REGENXBIO (NASDAQ:RGNX) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vericel has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.87	-$193.88M	-$3.79	N/A
Vericel	$276.26M	7.31	$16.52M	$0.47	83.91

In the previous week, REGENXBIO and REGENXBIO both had 3 articles in the media. Vericel's average media sentiment score of 0.78 beat REGENXBIO's score of 0.53 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

REGENXBIO has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Vericel has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Vericel has a net margin of 7.91% compared to REGENXBIO's net margin of -112.58%. Vericel's return on equity of 6.91% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Vericel	7.91%	6.91%	5.02%

REGENXBIO currently has a consensus target price of $23.27, suggesting a potential upside of 213.65%. Vericel has a consensus target price of $58.40, suggesting a potential upside of 48.07%. Given REGENXBIO's higher probable upside, research analysts clearly believe REGENXBIO is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Vericel beats REGENXBIO on 10 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to Mesoblast?

REGENXBIO (NASDAQ:RGNX) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Mesoblast has lower revenue, but higher earnings than REGENXBIO. Mesoblast is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.87	-$193.88M	-$3.79	N/A
Mesoblast	$120.25M	15.47	-$57.50M	-$0.28	N/A

Mesoblast has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Mesoblast's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Mesoblast	N/A	N/A	N/A

REGENXBIO has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

In the previous week, Mesoblast had 4 more articles in the media than REGENXBIO. MarketBeat recorded 7 mentions for Mesoblast and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.53 beat Mesoblast's score of 0.45 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

REGENXBIO presently has a consensus price target of $23.27, indicating a potential upside of 213.65%. Mesoblast has a consensus price target of $39.00, indicating a potential upside of 172.35%. Given REGENXBIO's stronger consensus rating and higher possible upside, equities analysts clearly believe REGENXBIO is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Mesoblast beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Agios Pharmaceuticals?

REGENXBIO (NASDAQ:RGNX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, REGENXBIO had 3 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 3 mentions for REGENXBIO and 0 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.79 beat REGENXBIO's score of 0.53 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
REGENXBIO	Positive
Agios Pharmaceuticals	Very Positive

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

REGENXBIO has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.87	-$193.88M	-$3.79	N/A
Agios Pharmaceuticals	$54.03M	35.89	-$412.78M	-$7.01	N/A

REGENXBIO has a net margin of -112.58% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

REGENXBIO has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

REGENXBIO currently has a consensus price target of $23.27, indicating a potential upside of 213.65%. Agios Pharmaceuticals has a consensus price target of $41.75, indicating a potential upside of 28.54%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities analysts plainly believe REGENXBIO is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Summary

REGENXBIO beats Agios Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does REGENXBIO compare to Lakefront Biotherapeutics American Depositary Shares?

REGENXBIO (NASDAQ:RGNX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

REGENXBIO currently has a consensus price target of $23.27, suggesting a potential upside of 213.65%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $37.00, suggesting a potential upside of 28.21%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts plainly believe REGENXBIO is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than REGENXBIO. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for REGENXBIO. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.91 beat REGENXBIO's score of 0.53 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than REGENXBIO. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.87	-$193.88M	-$3.79	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.51	$363.05M	-$1.41	N/A

REGENXBIO has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

Lakefront Biotherapeutics American Depositary Shares beats REGENXBIO on 9 of the 17 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$497.08M	$3.94B	$7.23B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-1.96	13.45	272.65	25.80
Price / Sales	2.87	1,293.92	607.73	90.99
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	3.66	15.66	10.51	6.26
Net Income	-$193.88M	-$22.67M	$3.50B	$360.95M
7 Day Performance	0.27%	-2.48%	-2.01%	-1.80%
1 Month Performance	-22.71%	-10.35%	-6.41%	-4.02%
1 Year Performance	-29.87%	21.99%	8.96%	2.18%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	3.1525 of 5 stars	$7.42 -1.5%	$23.27 +213.6%	-24.1%	$497.08M	$170.44M	N/A	371
KOD Kodiak Sciences	2.0532 of 5 stars	$32.22 -1.5%	$48.14 +49.4%	+524.7%	$2.02B	N/A	N/A	124	Trending News Analyst Forecast Insider Trade Analyst Revision
VCEL Vericel	3.3906 of 5 stars	$39.37 -1.6%	$58.40 +48.3%	+27.6%	$2.02B	$306.30M	83.77	398
MESO Mesoblast	2.2552 of 5 stars	$15.42 +1.9%	$39.00 +153.0%	-12.0%	$2.00B	$120.25M	N/A	108
AGIO Agios Pharmaceuticals	3.2367 of 5 stars	$33.51 +1.3%	$41.75 +24.6%	-18.9%	$2.00B	$54.03M	N/A	540	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. KOD, VCEL, MESO, AGIO, and LKFT

How does REGENXBIO compare to Kodiak Sciences?

Summary

How does REGENXBIO compare to Vericel?

Summary

How does REGENXBIO compare to Mesoblast?

Summary

How does REGENXBIO compare to Agios Pharmaceuticals?

Summary

How does REGENXBIO compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. KOD, VCEL, MESO, AGIO, and LKFT

How does REGENXBIO compare to Kodiak Sciences?

Do insiders & institutionals have more ownership in KOD or RGNX?

Which has more risk & volatility, KOD or RGNX?

Which has higher valuation and earnings, KOD or RGNX?

Does the media favor KOD or RGNX?

Is KOD or RGNX more profitable?

Do analysts rate KOD or RGNX?

Summary

How does REGENXBIO compare to Vericel?

Do institutionals and insiders hold more shares of RGNX or VCEL?

Which has stronger valuation & earnings, RGNX or VCEL?

Does the media refer more to RGNX or VCEL?

Which has more risk and volatility, RGNX or VCEL?

Is RGNX or VCEL more profitable?

Do analysts recommend RGNX or VCEL?

Summary

How does REGENXBIO compare to Mesoblast?

Which has stronger valuation and earnings, RGNX or MESO?

Is RGNX or MESO more profitable?

Which has more volatility and risk, RGNX or MESO?

Does the media favor RGNX or MESO?

Do institutionals & insiders have more ownership in RGNX or MESO?

Do analysts rate RGNX or MESO?

Summary

How does REGENXBIO compare to Agios Pharmaceuticals?

Does the media favor RGNX or AGIO?

Do institutionals and insiders hold more shares of RGNX or AGIO?

Which has higher valuation & earnings, RGNX or AGIO?

Is RGNX or AGIO more profitable?

Which has more risk & volatility, RGNX or AGIO?

Do analysts recommend RGNX or AGIO?

Summary

How does REGENXBIO compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts prefer RGNX or LKFT?

Is RGNX or LKFT more profitable?

Do insiders & institutionals have more ownership in RGNX or LKFT?

Does the media prefer RGNX or LKFT?

Which has better valuation & earnings, RGNX or LKFT?

Which has more risk and volatility, RGNX or LKFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools